Antiparkinson's Disease Drugs

Correct Answer

B — Serotonin-3 receptor antagonist

Rationale

Ondansetron is classified as a serotonin-3 receptor antagonist — a drug that blocks serotonin-3 receptors in the gastrointestinal tract and the chemoreceptor trigger zone to prevent nausea and vomiting. In the context of Parkinson's disease pharmacology, ondansetron is specifically contraindicated as antiemetic pretreatment before apomorphine therapy because the combination causes severe hypotension. Trimethobenzamide is the recommended antiemetic for this purpose instead. Ondansetron is not a dopamine agonist, a monoamine oxidase B inhibitor, or an anticholinergic agent.

Correct Answer

D — Pramipexole

Rationale

Pramipexole is approved for both Parkinson's disease and restless legs syndrome. Ropinirole shares this dual approval. Bromocriptine is an ergot-derived dopamine agonist whose use in Parkinson's disease has largely been replaced by non-ergot agents due to fibrosis risk; it is not approved for restless legs syndrome. Apomorphine is a subcutaneous rescue agent for acute off episodes in advanced Parkinson's disease and has no restless legs syndrome indication. Rotigotine is a transdermal non-ergot dopamine agonist used for Parkinson's disease; it does not share the restless legs syndrome approval that pramipexole and ropinirole carry.

Correct Answer

A — Reversible selective monoamine oxidase B inhibitor

Rationale

Safinamide is classified as a reversible selective monoamine oxidase B inhibitor. Its reversibility distinguishes it from selegiline and rasagiline, which are both irreversible selective monoamine oxidase B inhibitors — they form covalent bonds with the enzyme that persist until new enzyme is synthesized. Safinamide binds transiently, allowing enzyme activity to recover more readily. It is selective for the B isoform, distinguishing it from nonselective monoamine oxidase inhibitors such as phenelzine and tranylcypromine, which inhibit both monoamine oxidase A and monoamine oxidase B and are contraindicated with levodopa. Safinamide is approved only as adjunctive therapy with levodopa and is not used as monotherapy.

Correct Answer

C — Opioid analgesic

Rationale

Meperidine is classified as an opioid analgesic. It is relevant to Parkinson's disease pharmacology because it is absolutely contraindicated with all monoamine oxidase inhibitors — including selective monoamine oxidase B inhibitors such as selegiline and rasagiline. The combination can produce a severe serotonin syndrome-like reaction with hyperthermia, agitation, rigidity, and cardiovascular instability. This interaction is one of the highest-yield drug interaction facts in antiparkinson pharmacology. Meperidine is not a serotonin-3 receptor antagonist, a dopamine agonist, or a monoamine oxidase B inhibitor.

Correct Answer

B — Peripheral-and-central catechol-O-methyltransferase inhibitor

Rationale

Tolcapone is classified as a peripheral-and-central catechol-O-methyltransferase inhibitor — it crosses the blood-brain barrier and inhibits catechol-O-methyltransferase in both peripheral tissues and the brain. This distinguishes it from entacapone and opicapone, which are peripheral-only catechol-O-methyltransferase inhibitors and do not cross the blood-brain barrier. Tolcapone's dual site of action provides somewhat greater efficacy than entacapone, but it also carries a black box warning for potentially fatal hepatotoxicity, which limits its use to patients who have not responded adequately to other catechol-O-methyltransferase inhibitors. A central-only catechol-O-methyltransferase inhibitor subclass does not exist in current clinical use.

Correct Answer

D — Peripheral-only catechol-O-methyltransferase inhibitor

Rationale

Entacapone is classified as a peripheral-only catechol-O-methyltransferase inhibitor — it does not cross the blood-brain barrier and therefore acts exclusively in peripheral tissues to block levodopa metabolism. This distinguishes it from tolcapone, which inhibits catechol-O-methyltransferase in both peripheral tissues and the brain. Entacapone is the most widely used catechol-O-methyltransferase inhibitor because it lacks the hepatotoxicity risk associated with tolcapone and has an excellent safety record. It must be taken with each levodopa dose because of its short duration of action. Opicapone shares the peripheral-only classification but has a longer duration of action allowing once-daily dosing.

Correct Answer

B — Dopamine agonists have longer half-lives than levodopa, producing more continuous and sustained receptor stimulation

Rationale

Levodopa has a short plasma half-life of approximately one to two hours, producing sharp peaks and troughs of dopamine receptor stimulation in the striatum. After years of this pulsatile stimulation, motor complications — wearing-off and dyskinesias — develop. Dopamine agonists have substantially longer half-lives than levodopa and therefore stimulate dopamine receptors more continuously, producing a smoother and more sustained signal. This reduced pulsatility delays the receptor-level changes that underlie motor complications. When a dopamine agonist is used as initial monotherapy, the striatum is exposed to less pulsatile stimulation during the years before levodopa must be added, reducing the cumulative driver of motor complications. Dopamine agonists do not accumulate as active metabolites, are not cleared exclusively by renal routes as a class, and do not bind irreversibly to receptors — their duration of action is determined by their own plasma half-lives.

Correct Answer

D — D2 receptor stimulation

Rationale

D2 receptor stimulation in the striatum is responsible for the motor benefits of dopamine agonists in Parkinson's disease. D2 receptors are the primary therapeutic target of this drug class — their stimulation restores dopaminergic tone in the nigrostriatal pathway and reduces bradykinesia, rigidity, and tremor. D3 receptor stimulation contributes to behavioral effects rather than motor effects: D3 receptors are concentrated in the mesolimbic reward pathway, and their stimulation by dopamine agonists provides the pharmacological basis for impulse control disorders such as compulsive gambling and hypersexuality. D1 receptor stimulation is relevant to apomorphine, which has D1 and D2 activity, but D1 receptor engagement is not the basis for the motor benefit shared across the dopamine agonist class. D4 receptors play a role in antipsychotic pharmacology rather than antiparkinson therapy.

Correct Answer

A — D3 receptor stimulation in the mesolimbic reward pathway

Rationale

Impulse control disorders — including compulsive gambling, hypersexuality, compulsive eating, and compulsive shopping — are a class effect of dopamine agonists driven by D3 receptor stimulation in the mesolimbic reward pathway. D3 receptors are concentrated in the nucleus accumbens and other limbic structures that regulate reward-seeking behavior. When dopamine agonists stimulate these receptors, they can dysregulate the reward circuitry in ways that drive compulsive behaviors. This mechanism explains why impulse control disorders are a class effect of dopamine agonists and are seen at a much lower rate with levodopa alone — levodopa at therapeutic doses produces less direct mesolimbic D3 stimulation. D2 receptor stimulation in the nigrostriatal pathway produces the desired motor benefit. The mesocortical pathway is associated with cognitive function and is relevant to antipsychotic pharmacology.

Correct Answer

C — Sleep attacks

Rationale

Sleep attacks — the sudden onset of sleep without warning drowsiness — are a class-defining adverse effect of dopamine agonists that is more prominent with this drug class than with levodopa alone. Patients can fall asleep abruptly while driving, eating, or engaged in conversation, creating serious safety risks. All patients starting dopamine agonist therapy must be specifically counseled about the risk of sleep attacks and advised not to drive or operate machinery until their individual response to the drug is established. Impulse control disorders are a second class-defining effect. Orthostatic hypotension and nausea occur with both dopamine agonists and levodopa through shared peripheral dopaminergic mechanisms and are not specifically defining for the agonist class. Hallucinations occur with both drug classes through mesolimbic dopamine excess.

Correct Answer

B — Pramipexole is renally excreted, and reduced kidney function decreases its clearance, causing accumulation at standard doses

Rationale

Pramipexole is excreted primarily unchanged by the kidneys. When renal function is reduced, the clearance of pramipexole falls proportionally, causing the drug to accumulate in the body at doses that would be appropriate in a patient with normal kidney function. Accumulation increases the risk of adverse effects, including orthostatic hypotension, hallucinations, and impulse control disorders. Dose reduction — or in severe renal impairment, longer dosing intervals — is required to maintain safe plasma concentrations. Pramipexole does not undergo significant hepatic first-pass metabolism, its protein binding is not substantially altered by renal disease, and it is not converted to active metabolites by renal tubular enzymes. This pharmacokinetic property contrasts with ropinirole, which is hepatically metabolized via the cytochrome P450 1A2 enzyme and therefore has a different elimination profile.

Correct Answer

D — Hepatic metabolism via cytochrome P450 1A2

Rationale

Ropinirole is primarily eliminated by hepatic metabolism via the cytochrome P450 1A2 enzyme. This pharmacokinetic property has clinical implications: drugs that inhibit cytochrome P450 1A2 — such as ciprofloxacin or fluvoxamine — can increase ropinirole plasma levels and potentially enhance its adverse effects. Conversely, cytochrome P450 1A2 inducers such as smoking can reduce ropinirole levels. Pramipexole, by contrast, is excreted primarily unchanged by the kidneys and is therefore more affected by changes in renal function than by hepatic enzyme inhibitors or inducers. Renal excretion of unchanged drug describes pramipexole. Biliary excretion as glucuronide conjugates and spontaneous plasma hydrolysis describe elimination routes for other drug classes — ropinirole elimination is driven by hepatic cytochrome P450 1A2 metabolism.

Correct Answer

A — Dopamine agonists act directly at dopamine receptors and do not depend on surviving neurons to produce or store dopamine

Rationale

Dopamine agonists bypass the degenerating nigrostriatal neurons entirely — they bind directly to dopamine receptors in the striatum without requiring any surviving neuron to synthesize, store, or release dopamine first. This is their fundamental mechanistic advantage over levodopa in advanced disease. Levodopa depends on surviving neurons for two things: conversion to dopamine by aromatic amino acid decarboxylase, and storage and buffering of the dopamine produced to smooth out the peaks and troughs of each oral dose. As neurons are lost, both of these capacities diminish, and wearing-off and motor fluctuations develop. Dopamine agonists have their own plasma half-lives and receptor affinity independent of neuronal function, so their effectiveness is determined by their own pharmacokinetics rather than by the residual capacity of the degenerating nigrostriatal system. Dopamine agonists do not upregulate receptors, stimulate neurogenesis, or have any immunomodulatory effect on the neurodegenerative process.

Correct Answer

C — Apomorphine is a potent dopamine agonist that strongly stimulates dopamine receptors in the chemoreceptor trigger zone

Rationale

Apomorphine causes severe nausea because it is a highly potent dopamine agonist that strongly stimulates dopamine receptors in the chemoreceptor trigger zone — the emesis-triggering region of the medulla that lies outside the blood-brain barrier and is exposed to circulating drug. The chemoreceptor trigger zone responds to apomorphine as a strong emetogenic signal, triggering the vomiting reflex. This mechanism is shared with other dopamine agonists, but apomorphine's high potency and rapid delivery by subcutaneous injection make the emetogenic effect particularly severe. Trimethobenzamide is specifically chosen as the antiemetic pretreatment because it does not block striatal dopamine receptors and therefore does not worsen motor symptoms. Apomorphine is administered subcutaneously, bypassing gastrointestinal absorption and first-pass metabolism. It does not activate serotonin-3 receptors — that class of receptors is blocked by ondansetron, which is contraindicated with apomorphine due to the risk of severe hypotension.

Correct Answer

D — Fibrotic reaction associated with the ergot chemical scaffold of bromocriptine

Rationale

This patient's pulmonary fibrosis is a known adverse effect of ergot-derived dopamine agonists. The ergot chemical scaffold — shared by bromocriptine and other ergot-derived compounds — is associated with fibrotic reactions at multiple sites: retroperitoneal, pulmonary, and cardiac valve fibrosis. The mechanism involves serotonin-mediated fibroblast activation driven by the ergot moiety rather than by dopamine receptor stimulation. This fibrotic potential is entirely absent from non-ergot dopamine agonists such as pramipexole, ropinirole, and rotigotine, which is why ergot-derived agents have been largely replaced in clinical practice. Bromocriptine has no anticholinergic activity. Its metabolites do not accumulate in lung tissue in a toxic fashion. Dopamine receptor stimulation in pulmonary vasculature does not explain the pleural thickening seen with ergot-derived agents.

Correct Answer

B — Reduce or discontinue pramipexole and transition to levodopa-carbidopa to eliminate D3 receptor stimulation in the mesolimbic pathway

Rationale

This patient's compulsive gambling is a dopamine agonist-induced impulse control disorder driven by D3 receptor stimulation in the mesolimbic reward pathway. Pramipexole has particularly high D3 affinity, making it among the more likely dopamine agonists to cause this adverse effect. The most direct pharmacological solution is to reduce or discontinue pramipexole and replace it with levodopa-carbidopa — levodopa at therapeutic doses produces much less direct D3 stimulation in the mesolimbic pathway than dopamine agonists, and impulse control disorders typically resolve when the agonist is withdrawn. Adding a selective serotonin reuptake inhibitor addresses mood rather than the underlying dopaminergic mechanism. Bromocriptine is an ergot-derived dopamine agonist and also stimulates D2 receptors with dopaminergic activity in the mesolimbic pathway — switching to it would not reliably eliminate the D3-mediated impulse dyscontrol. Catechol-O-methyltransferase inhibitors extend levodopa availability and have no mechanism to reduce mesolimbic D3 stimulation from a dopamine agonist.

Correct Answer

A — Ondansetron combined with apomorphine causes severe hypotension

Rationale

Ondansetron and other serotonin-3 receptor antagonists are specifically contraindicated with apomorphine because the combination produces severe hypotension — a potentially life-threatening cardiovascular interaction. The precise mechanism of this interaction is not fully characterized but is a well-established clinical finding that led to contraindication labeling. Trimethobenzamide is the recommended antiemetic for apomorphine pretreatment because it does not carry this interaction risk. It also has the advantage of not blocking striatal dopamine receptors, so it does not worsen motor symptoms. Ondansetron has no meaningful dopamine receptor blocking activity in the striatum. It does not inhibit the cytochrome P450 enzymes involved in apomorphine metabolism. Absorption site competition is not a pharmacologically meaningful interaction between these agents.

Correct Answer

C — Peripheral dopamine receptor stimulation causing vasodilation and activating the chemoreceptor trigger zone

Rationale

Orthostatic hypotension and nausea are both class-wide adverse effects of dopamine agonists caused by peripheral dopamine receptor stimulation. Pramipexole, like other dopamine agonists, stimulates dopamine receptors in peripheral blood vessel walls — causing vasodilation that reduces vascular resistance and produces orthostatic hypotension when the patient stands. It also stimulates dopamine receptors in the chemoreceptor trigger zone of the medulla, which lies outside the blood-brain barrier and is exposed to circulating drug, triggering nausea. Both effects are most prominent during initiation of therapy and with dose increases, and are managed by starting at low doses and titrating slowly. Pramipexole does not block norepinephrine receptors or inhibit norepinephrine synthesis, and its central effects are mediated by striatal and mesolimbic dopamine receptors rather than hypothalamic autonomic centers.